ArriVent BioPharma, Inc. (AVBP)Healthcare | Biotechnology | Newtown Square, United States | NasdaqGM
30.17 USD
-0.83
(-2.677%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 30.17 |
Hot Take ↕ | Aug. 22, 2026, 1:13 a.m. EDT
ArriVent BioPharma presents a stark dichotomy between its pristine balance sheet and its deteriorating business trajectory. Fundamentally, the company holds a fortress-like balance sheet with negligible debt and massive cash reserves relative to obligations, yet it is burning through free cash flow rapidly while posting negative returns on equity and assets. The stock has already punished investors with a 15.75% decline over the last year, and the lack of any dividend history confirms this is a pure growth/speculative play with no income floor. The short-term outlook remains murky. While analysts offer a strong buy recommendation based on potential catalysts like the EGFR Firmonertinib trials, the price action has been flat to slightly negative recently, trading below its 50-day moving average. The statistical forecasting model offers almost no directional guidance, reinforcing the idea that the stock is currently in a state of uncertainty rather than a clear trend. The heavy put activity suggests traders are hedging against a potential failure of upcoming trials or further delays, which could trigger a significant gap down. Long-term, the investment case rests entirely on the success of its clinical pipeline. Without a successful product launch to reverse the negative earnings trends, the company faces the classic biotech risk of running out of cash or diluting shareholders to survive. Until the company demonstrates sustained revenue growth or a clear path to profitability, the fundamental risks outweigh the speculative upside. This is a high-risk venture capital play disguised as a public stock, suitable only for investors willing to accept the possibility of total capital loss in exchange for a lottery ticket on a drug trial. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.065696 |
| AutoETS | 0.065888 |
| AutoARIMA | 0.065890 |
| MSTL | 0.067117 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 0.65 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.346 |
| Excess Kurtosis | -1.06 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.096 |
| Market Cap | 1,487,614,208 |
| Forward P/E | -7.93 |
| Beta | 1.37 |
| Website | https://arrivent.com |
As of Aug. 22, 2026, 1:13 a.m. EDT: Speculators are positioning defensively with heavy put volume at strikes significantly below the current price (e.g., $15, $25), suggesting a fear of a sharp decline or a 'double the money' trade on a crash. Conversely, there is notable open interest in deep out-of-the-money calls ($40, $50), indicating asymmetric bets on a massive rally driven by trial results. However, the immediate expiration shows a distinct lack of call volume compared to puts, reflecting a cautious near-term outlook despite the long-dated bullish speculation.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5625 |
| Address1 | 18 Campus Boulevard |
| Address2 | Suite 100 |
| All Time High | 36.37 |
| All Time Low | 14.35 |
| Ask | 38.95 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 445,790 |
| Average Daily Volume3 Month | 554,433 |
| Average Volume | 554,433 |
| Average Volume10Days | 445,790 |
| Beta | 1.366 |
| Bid | 22.54 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 7.592 |
| City | Newtown Square |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 30.17 |
| Current Ratio | 14.156 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 31.37 |
| Day Low | 29.75 |
| Debt To Equity | 0.096 |
| Display Name | ArriVent BioPharma |
| Earnings Timestamp End | 1,794,859,200 |
| Earnings Timestamp Start | 1,794,859,200 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 1,114,846,208 |
| Eps Current Year | -4.34262 |
| Eps Forward | -3.80589 |
| Eps Trailing Twelve Months | -3.47 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 31.5809 |
| Fifty Day Average Change | -1.4109001 |
| Fifty Day Average Change Percent | -0.04467574 |
| Fifty Two Week Change Percent | 56.25 |
| Fifty Two Week High | 35.83 |
| Fifty Two Week High Change | -5.6600018 |
| Fifty Two Week High Change Percent | -0.15796822 |
| Fifty Two Week Low | 17.0 |
| Fifty Two Week Low Change | 13.17 |
| Fifty Two Week Low Change Percent | 0.7747059 |
| Fifty Two Week Range | 17.0 - 35.83 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,706,279,400,000 |
| Float Shares | 32,106,235 |
| Forward Eps | -3.80589 |
| Forward P E | -7.9271865 |
| Free Cashflow | -89,478,496 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 77 |
| Fullday Change | -0.83 |
| Fullday Change Percent | -2.67742 |
| Fullday Price | 30.17 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01543 |
| Held Percent Institutions | 0.98682 |
| Implied Shares Outstanding | 49,307,729 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-01-26 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania. |
| Long Name | ArriVent BioPharma, Inc. |
| Market | us_market |
| Market Cap | 1,487,614,208 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1671738162 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -164,210,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,525,581,135 |
| Number Of Analyst Opinions | 10 |
| Open | 30.53 |
| Operating Cashflow | -147,928,992 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 628 277 4836 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 30.17 |
| Post Market Time | 1,787,947,805 |
| Previous Close | 31.0 |
| Price Eps Current Year | -6.947419 |
| Price Hint | 2 |
| Price To Book | 3.9739199 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.4 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.83 |
| Regular Market Change Percent | -2.67742 |
| Regular Market Day High | 31.37 |
| Regular Market Day Low | 29.75 |
| Regular Market Day Range | 29.75 - 31.37 |
| Regular Market Open | 30.53 |
| Regular Market Previous Close | 31.0 |
| Regular Market Price | 30.17 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 353,458 |
| Return On Assets | -0.33110002 |
| Return On Equity | -0.53253 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 49,307,729 |
| Shares Percent Shares Out | 0.16690001 |
| Shares Short | 8,227,393 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 7,665,375 |
| Short Name | ArriVent BioPharma, Inc. |
| Short Percent Of Float | 0.177 |
| Short Ratio | 17.26 |
| Source Interval | 15 |
| State | PA |
| Symbol | AVBP |
| Target High Price | 50.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 44.7 |
| Target Median Price | 45.0 |
| Total Cash | 373,119,008 |
| Total Cash Per Share | 7.567 |
| Total Debt | 351,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.47 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 26.39825 |
| Two Hundred Day Average Change | 3.7717495 |
| Two Hundred Day Average Change Percent | 0.14287877 |
| Type Disp | Equity |
| Volume | 353,458 |
| Website | https://arrivent.com |
| Zip | 19,073 |